18 Adrenocortical Carcinoma (ACC) Clinical Trials Recruiting Now (June 2026): Mitotane, Cabozantinib + Cemiplimab, Pembrolizumab, Ivonescimab, DS9051b, mRNA Vaccine
Last updated: June 9, 2026
Current Clinical Trial Landscape
About adrenocortical carcinoma (ACC):
ACC is a rare and aggressive cancer of the adrenal cortex. ~1-2 cases per million per year. Often diagnosed at advanced stages. Can be functional (hormone-producing) or non-functional.
Active research areas in 2026:
- Checkpoint inhibitors (pembrolizumab, dostarlimab Pan-MSI-ACSE, cemiplimab maintenance INTERVAL)
- Bispecific antibodies (ivonescimab PD-1/VEGF, rare-tumor basket)
- Cabozantinib + IO combinations (with cemiplimab or pembrolizumab)
- Targeted combinations (camrelizumab + apatinib; PD-1 + apatinib + mitotane)
- Mitotane combinations (adjuvant Ph3; PD-1 + apatinib first-line)
- Antibody-drug conjugates (ADCT-701, DLK1-targeting)
- First-in-human novel agents (DS9051b, Daiichi Sankyo)
- mRNA neoantigen vaccines for advanced endocrine tumors
- Hormone-based combinations (progesterone + chemo, PESETA)
Standard of care: Resectable: surgery + adjuvant mitotane. Unresectable/metastatic: mitotane + etoposide/doxorubicin/cisplatin (EDP-M). Limited second-line options.
Recruiting Trials by Treatment Setting
Adjuvant Therapy
After surgery for resectable disease:
- NCT03583710 - Mitotane ± cisplatin/etoposide after surgery in ENSAT stage I-III ACC (MD Anderson, Phase 3)
First-Line Metastatic
For newly diagnosed advanced disease:
- NCT06831175 - PD-1 inhibitor + apatinib + mitotane (West China Hospital, Phase 2)
Second-Line and Beyond
After progression on mitotane-based therapy:
- NCT04318730 - Camrelizumab + apatinib in recurrent/metastatic ACC second-line (West China Hospital, Phase 2)
- NCT05563467 - Pembrolizumab monotherapy in advanced progressive ACC (PEMBR-01, Maria Sklodowska-Curie, Phase 2)
- NCT06006013 - Cabozantinib + pembrolizumab in locally advanced/metastatic ACC (Emory, Phase 2)
- NCT06900595 - Cabozantinib + cemiplimab in locally advanced/metastatic/recurrent ACC (NCI, Phase 2)
Trials by Treatment Approach
Checkpoint Inhibitors
Immunotherapy trials for ACC:
- NCT06333314 - Dostarlimab in dMMR/MSI-H non-colorectal/non-endometrial cancers including ACC (Pan-MSI-ACSE, UNICANCER, Phase 2)
- NCT07085572 - Cemiplimab as maintenance for advanced ACC (INTERVAL, ASST Italy, Phase 2)
- NCT06066333 - Radiotherapy + pembrolizumab in ACC (MSK, Phase 2)
- NCT06587802 - PD-1 antibody + radiotherapy in recurrent/metastatic ACC (Sun Yat-sen, Phase 2)
Bispecific Antibodies / Rare-Tumor Basket
- NCT06683846 - Ivonescimab (PD-1/VEGF bispecific) in a 20-cohort rare-tumor basket including adrenal cortical cancer (cohort 10) (Fudan University Cancer Hospital, Phase 2)
Targeted Therapy & First-in-Human
- NCT07189403 - DS9051b first-in-human in advanced/metastatic ACC and mCRPC (Daiichi Sankyo, Phase 1)
Regional Therapies
- NCT05286814 - PDS01ADC + HAIP (hepatic artery infusion pump) + systemic therapy (NCI, Phase 2)
- NCT06487481 - Preoperative radiation in resectable recurrent abdominal ACC (NCI, Phase 1)
mRNA Neoantigen Vaccine
- NCT06141369 - Individualized mRNA neoantigen vaccine (mRNA-0523-L001) for advanced endocrine tumors including ACC, medullary thyroid, thymic and pancreatic NET (Shanghai Jiao Tong)
Antibody-Drug Conjugates
- NCT06041516 - ADCT-701 (DLK1-targeting ADC) first-in-human in neuroendocrine and adrenocortical carcinomas (NCI, Phase 1)
CAR-T Cell Therapy
- NCT04897321 - B7-H3-specific CAR-T autologous T-cell therapy for pediatric solid tumors including ACC (St. Jude, Phase 1)
Hormone-Based Approaches
- NCT05913427 - Progesterone + standard chemotherapy in ACC (PESETA, ASST Italy, Phase 2)
View all 18 adrenocortical carcinoma trials on ClinicalTrials.gov →
Frequently Asked Questions
How do I find adrenocortical carcinoma clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched adrenal cancer trials in minutes. The tool considers your tumor stage, mitotane treatment history, and hormonal status.
What adrenocortical carcinoma trials are currently recruiting?
There are 18 recruiting interventional trials for adrenocortical carcinoma including immunotherapy (pembrolizumab, dostarlimab, cemiplimab, ivonescimab PD-1/VEGF bispecific), targeted combinations (cabozantinib + IO, camrelizumab + apatinib, PD-1 + apatinib + mitotane), novel agents (DS9051b first-in-human, ADCT-701 DLK1 ADC), and mRNA neoantigen vaccine.
Find ACC Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific stage and treatment history.
Find Matching Trials
